Finding the shortest path from physics to medicine.
Ab Initium develops biotechnology at the intersection of physics and biology, creating new ways to design medicines from the physical principles that govern molecular interaction.
Ab Initium develops biotechnology at the intersection of physics and biology, creating new ways to design medicines from the physical principles that govern molecular interaction.
ab initium is a physician-led biotechnology company. Our platform is built on a patent-protected mathematical and logical framework that treats molecular design as transparent, reproducible methods — not as black-box pattern matching.
Every candidate we produce is computed from physics and scored against the same first principles — fully traceable, end to end. We work across modalities, from de novo design to refinement of existing leads, in partnership with pharmaceutical and biotech sponsors.
This antibody was fully generated and validated in silico — the heavy-chain framework (blue) and light-chain framework (green) bind and capture the antigen site with no clashes. Contact residues identified by the platform line the small-molecule pose at center with more favorable energetic interactions than well-established antibodies — all designed, ranked, and audited within a single deterministic pipeline.
Generate new antibody and small-molecule candidates against defined targets, grounded in mechanistic physics rather than learned correlations.
Refine existing leads for affinity, selectivity, developability, and manufacturability with transparent, reproducible trade-offs.
Physics-grounded scoring with auditable provenance, gating candidates on safety, specificity, and reproducibility before resources commit.
Engagements typically begin with a confidential scoping conversation. We respond to qualified inquiries within two business days.
Contact us →